Human EGFR-2, EGFR and HDAC triple-inhibitor CUDC-101 enhances radiosensitivity of GBM cells

Radiotherapy remains the standard treatment for glioblastoma multiforme (GBM) following surgical resection. Given the aberrant expression of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) which may play a role in therapeutic resistance to receptor tyrosin...

Descripció completa

Dades bibliogràfiques

Autors principals:	Cody D Schlaff, W Tristram Arscott, Ira Gordon, Kevin A Camphausen, Anita Tandle
Format:	Artigo
Idioma:	Inglês
Publicat:	Wolters Kluwer Medknow Publications 2015-01-01
Col·lecció:	Biomedical Research Journal
Matèries:	glioblastoma multiforme radiosensitization hdac multi-target therapy her2 egfr
Accés en línia:	http://www.brjnmims.org/article.asp?issn=2349-3666;year=2015;volume=2;issue=1;spage=105;epage=119;aulast=Schlaff;type=0
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!